Business Summary

Amarin is a clinical-stage biopharmaceutical company focused on developing treatments for cardiovascular disease. The Company is focusing its studies on AMR101 (icosapent ethyl), a prescription-only omega-3 fatty acid. The Company is developing AMR101 for the treatment of patients with very high triglyceride levels and high triglyceride levels, or hypertriglyceridemia. Triglycerides are fats in the blood.

Data provided by Mergent, Inc.

Recent Company News

Powered by Interactive Data Managed Solutions
DR Symbol AMRN
CUSIP 023111206
DR Exchange NASDAQ Stock Market
DR ISIN US0231112063
Ratio 1:1
Depositary CIT (Sponsored)
Effective Date Apr 08, 1993
Country United Kingdom
Industry Pharma. & Biotech.

Powered by Interactive Data Managed Solutions

Monthly DR Trading Summary

Month Month End
DR Close
Price
DR Trading Volume Avg Day DR
Trading
Volume
Apr. 13 7.41 80,277,708 3,648,987
Mar. 13 7.41 77,946,118 3,897,306
Feb. 13 8.09 56,920,942 2,995,839
Data provided by Interactive Data Corp.

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to
"Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

© 2013 The Bank of New York Mellon Corporation. Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Quotes delayed at least 15 minutes.Market data provided by Interactive Data
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Certain information included in this website is proprietary to Mergent, Inc. (Mergent) Copyright © 2003-2010. Reproduction of such information in any form is prohibited. Because of the possibility of
human or mechanical error by Mergent's sources, Mergent or others, Mergent does not guarantee the accuracy, adequacy, completeness, timeliness or availability or for the results obtained from the
use of such information. Mergent Terms of Use apply

Holdings information provided by FactSet Research Systems Inc. Copyright © 2003-2013 FactSet Research Systems Inc. All rights reserved.

DR Calendar provided by Thomson Reuters, Inc. © 2013 The Thomson Reuters Corporation. All Rights Reserved. Terms of Use. Privacy Statement.
Send questions, comments or suggestions to corporateservices@thomsonreuters.com